Using a model of colon carcinoma, Radojcic et al. published in 2010 a report that showed low- to moderate-dose CPX was capable of triggering increased production of IL-12 and tumor necrosis factor (TNF)-α, key indicators of Th1 immunity [18]. The gene discussed is TNF; the disease is colon carcinoma.